\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Research Infrastructures HealthThe first four COVID-19 call topics are published on the Funding and Tender portal (keyword covid). The opening of the calls is postponed from 13 April (as was previously communicated) to 15 April, due to technical problems with the submission system on the Funding and Tender portal. However the necessary information and documents are already available on the portal.
Two topics are taken up in the Health work programme:
- HORIZON-HLTH-2021-CORONA-01-01: vaccine & therapeutic clinical trials to boost COVID-19 prevention and treatment
- HORIZON-HLTH-2021-CORONA-01-02: cohorts united against COVID-19 variants of concern
Two topics are included in the Research infrastructure work programme:
- HORIZON-INFRA-2021-EMERGENCY-01: FAIR and open data sharing in support to European preparedness for COVID-19 and other infectious diseases
- HORIZON-INFRA-2021-EMERGENCY-02: infrastructure services for rapid research responses to Covid-19 and other infectious disease epidemics
The recording of the dedicated information webinar on these four calls is available here https://webcast.ec.europa.eu/horizon-europe-focused-actions-in-research-infrastructures-and-health-to-target-covid-19-variants
European Commission press release
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
